Janssen secures a ‘yes, but’ MSAC response as Gilead strengthens its lead with an important recommendation and expanded people focus.
Funding details of BioMarin’s gene therapy revealed along with insights into AstraZeneca and Astellas’ new targeted cancer therapies.
More than two years after its initial recommendation, Australians are finally close to funded access for the country’s third cell therapy.
Entrepreneur Michelle Gallaher named inaugural CEO of Cerulea, a new clinical trial centre investigating gene therapies for eye disorders.
Study of 13 new products across 20 countries found Australia lagged well behind others in reimbursing cell and gene therapies.
Gets an all-important tick in the US as bluebird bio’s CAR T-cell therapy secures FDA approval for the same blood disease.
Planning to develop and commission a state-of-the-art mRNA clinical-scale manufacturing facility at the University’s Melbourne campus.
The long-awaited response to the House of Reps report is here. See which of its 31 recommendations got a green light.